Angiotensin II receptor blockers represent a class of effective and well tolerated orally active antihypertensive drugs. Activation of AT 1 receptors leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone and promote growth of vascular and cardiac muscle. AT 1 receptor blockers antagonise all those effects. Losartan was the first drug of this class marketed, shortly followed by valsartan, irbesartan, telmisartan, candesartan, eprosartan and others on current investigation. All these drugs have the common properties of blockading the AT 1 receptor thereby relaxing vascular smooth muscle, increase salt excretion, decrease cellular hypertrophy and induce antihypertensive effect without modifying heart rate or cardiac output. Most of the AT 1 receptor blockers in use controlled blood pressure during the 24 h with a once-daily dose, without evidence of producing tolerance to the antihypertensive effect and being
Introduction
The renin-angiotensin system is integrally involved in maintaining the healthy body's haemodynamic status. Angiotensin II is the prime effector molecule of the renin-angiotensin-aldosterone system, inducing vasoconstriction, promotion of cell growth in vascular and myocardial tissue, activation of the sympathetic nervous system and producing sodium and fluid retention. Most of these cardiovascular effects of angiotensin II are mediated by AT 1 receptors. Selective blockade of the AT 1 receptor not only inhibits vasoconstriction and vascular hypertrophy, but also could lead to a compensatory increase in angiotensin II levels. These increased concentrations of angiotensin II may confer additional pharmacological benefits by stimulating the AT 2 receptor subtype, which has been reported to mediate antiproliferative actions on cardiac and vascular smooth muscle.
Salarasin was the first receptor antagonist of angiotensin II available for clinical use more than 20 years ago. 4, 5 Salarasin is a peptide analogue of angiotensin II with partial agonist effect, and can only be used intravenously; it has a very short duration of action. When saralasin is used there is an initial increase in arterial blood pressure due to its partial agonist effect, but prevents the increment of blood pressure when angiotensin II is administrated.
Furukawa et al 6 was the first to synthesise an imidazole derivative that was found to be a selective angiotensin II receptor competitive antagonist, and after chemical modifications, orally active agent. 7 Losartan was the first orally active and long-acting receptor antagonist developed and in use in the treatment of hypertension, 8, 9 followed by valsartan, irbesartan, eprosartan, candesartan, telmisartan and others. 10 Blockade of renin-angiotensin system is efficacious and a safe way to reduce blood pressure as treatment of patients with hypertension, mainly by the inhibition of angiotensin-converting enzyme (ACE). The main side effects observed with ACE inhibitors are cough and angioedema, which are seen in 5 to 10% of patients treated with this drug class.
11 AT 1 receptor blockers have the advantage in having a very low incidence of such side effects. However the place of this class of antihypertensive action remains to be defined.
Angiotensin II receptors
Angiotensin II (AII) exerts its effects by stimulating some specific receptors on the membrane of several organs. Radioligand studies have characterised several angiotensin II receptors, mainly type I and type II (AT 1 and AT 2 receptors). Activation of AT 1 receptors leads to vasoconstriction, stimulation of the release of catecholamines and antidiuretic hormone and production of thirst; also promoting growth effects in vascular and cardiac muscle, 12 all these effects are blocked by AT 1 antagonists. Several AT 1 receptor antagonists are now available for clinical use. Experimental studies have shown interesting differences in their binding properties and the pattern of inhibition of contractile responses to angiotensin II in isolated blood vessels. [13] [14] [15] In human subcutaneous resistance arteries the AT 1 receptor antagonists, candesartan, losartan and losartan's metabolite EXP-3174, reduce the maximal contractile response to AII suggestive of non-competitive antagonism. In the case of losartan the concentration-response curve also appears to be displaced by higher concentrations of AII, giving the overall appearance of mixed competitive and noncompetitive antagonism. 13 These observations differ from those obtained in rabbit and rat vessels where losartan appears to behave as a competitive antagonist 16, 17 in contrast with candesartan which acts in a non-competitive manner. 18 Eprosartan differs from other agents in its class in that it is a non-biphenyl, non-tetrazole, competitive angiotensin II receptor antagonist with a high affinity for AT 1 subtype. In addition, eprosartan also differs from other angiotensin II receptor antagonists by providing combined inhibition of both the renin-angiotensin system and the sympathetic nervous system, as demonstrated in pithed rats. 19, 20 In contrast to the AT 1 subtype, the physiological role of the AT 2 receptor has long remained an enigma. This subtype is highly expressed in fetal tissues, whereas its expression is dramatically decrease after birth, being restricted to a few organs such as brain, adrenal, heart, myometrium and ovary. The AT 2 receptors are re-expressed during stressful situations in the adult animal, after cardiac and vascular injury (such as myocardial infarction, left ventricular hypertrophy and in vascular neointimal proliferation), also nerve crush and during wound healing, kidney obstruction and sodium depletion. This suggests a role for this receptor in tissue remodelling, growth and/or development. A major step towards the understanding of AT 2 receptor functions has recently been provided by the generation of genetically engineered animals either lacking or over-expressing the gene encoding the AT 2 receptor. [21] [22] [23] [24] The effect of the AT 1 receptor antagonists might be a result of the blockade of the AT 1 receptor and stimulation of the AT 2 receptor, because increased angiotensins might act preferentially on the AT 2 receptor when the AT 1 receptor is blocked. 25 It may be possible that the AT 2 receptor plays a role in the pathogenesis and remodelling of cardiovascular diseases, further understanding of AT 2 receptors could contribute to new therapeutic strategies for cardiovascular disease and hypertension.
Actions mediated by AT 1 and AT 2 receptors are summarised in Table 1 . Other angiotensin II receptors have been described such as AT 3 and AT 4 26 in rats and mice; AT 1 receptor is also composed of two subtypes: AT 1A and AT 1B ; 27 these receptors have to be characterised pharmacologically and in pathophysiological conditions.
AT 1 receptor antagonists
The first chemically useful, orally active AT 1 receptor antagonist was losartan, followed by other agents currently in clinical use or under investigation. 8, 9 They have a high affinity of AT 1 receptor subtype without exerting agonistic effects and do not bind to the AT 2 receptor when given at the recommended clinical doses. Likewise, specific inhibitors of the AT 2 receptor do not bind to the AT 1 receptor. 28, 29 The AT 1 receptor antagonist reduce blood pressure by decreasing systemic vascular resistance; heart rate and cardiac output are not modified. [30] [31] [32] Reduction in systemic vascular resistance are due to inhibition of the direct vasoconstrictive effect of angiotensin II, reductions in the sympathetic nervous system activity, in the release of aldosterone and in the re-absorption of sodium, are mediated by angiotensin II. It has also been described as sensitising in baroreceptors, the stimulation of prostacyclin release, and at long-term reduction in the proliferative effect (antiproliferative effect). 10 In volunteers the administration of AT 1 receptor antagonists increase plasma renin activity and angiotensin II levels either in acute administration or multiple dose administration; 33, 34 but the pressure effect of angiotensin II is blocked. Whereas, ACE inhibitors reduce plasma level of angiotensin II increasing bradykinin levels.
The efficacy in reducing blood pressure with the use of AT 1 receptor antagonists is equivalent to other well established antihypertensive agents. When losartan (50 to 100 mg daily) is compared to felodipine (5 to 10 mg daily, losartan was less effective after 6 weeks of treatment but equally effective after 12 weeks of therapy). 35 The efficacy of losartan (50 to 100 mg once daily) has been compared to atenolol (50 to 100 mg once daily), and enalapril (20 mg once daily). The blood pressure lowering effect of losartan was comparable to enalapril and atenolol. On ambulatory blood pressure monitoring losartan showed antihypertensive effect over a period of 24 h without affecting the body's circadian rhythm. 36, 37 Several studies have compared the blood pressure lowering effects of AT 1 receptor antagonists against enalapril; candesartan cilexitil, 38 eprosartan 39 and irbesartan 40 lower systolic and diastolic blood pressure to the same extent to that of enalapril.
In a study of severe hypertensive patients, eprosartan has been shown to be as effective as enalapril in lowering diastolic blood pressure and superior to enalapril in reducing systolic blood pressure. 41 In a 10-week, randomised, multicentre, double-blind, parallel-group trial, 118 patients (78% aged Ͻ65 years and 22% aged у65 years) with severe hypertension (diastolic blood pressure у115 mm Hg and р125 mm Hg) were randomly assigned to receive either eprosartan (400-800 mg per day, given twice daily) or enalapril (10-40 mg once daily). The
Journal of Human Hypertension results showed that eprosartan reduced seated systolic blood pressure by 29 mm Hg in comparison with a reduction of 21 mm Hg in those taking enalapril (P Ͻ 0.05). 41 When diuretics were added to an AT 1 receptor antagonist, a better response is achieved. The addition of hydrochorothiazide to losartan produces a dose-related reduction in blood pressure after a treatment of 12 weeks. 36 In a double-blind study 189 patients were enroled to compare valsartan + HCTZ (12.5 mg) and enalapril + HCTZ (12.5 mg), which after 8 weeks of treatment controlled blood pressure in about 64% of the patients in both group of treatments. 42 Losartan has been shown to exert a uricosuric effect in normotensive and hypertensive subjects, which could be an advantage when losartan is combined with a thiazide diuretic. 37 At 4 h after single doses of 100 mg of losartan, serum uric acid levels were reduced by approximately 20% and urinary excretion of uric acid was increased. 43 This uricosuric effect was maintained after administration of losartan once daily for 7 days. The clinical significance of the uricosuric effect remains to be established; however, is a special indication when patient has hyperuricemia or goat.
Pharmacokinetic
Angiotensin AT 1 receptors antagonists in clinical use essentially seem to share about the same pharmacodynamic characteristics with only very few differences; but these agents differ in their pharmacokinetic characteristics in terms of oral bioavailability, rate of absorption, metabolism, route and rate of elimination, duration of action and half-life. Table 3 summarises the pharmacokinetic of some AT 1 receptor antagonists in current use. Losartan potassium undergoes extensive first-pass metabolism and is converted into EXP3174 in the liver. 44, 45 Peak concentrations of losartan are achieved by 1 h after administration, whereas EXP3174 reaches peak levels at 3.5 h; both losartan and EXP 3174 are active, as antihypertensive and AT 1 receptor blocker, in fact EXP 3174 prolong the antihypertensive effect. On the other hand, candesartan cilexetil is a pro-drug that is converted to active drugs in vivo. After oral administration, in contrast, candesartan cilexetil is fully converted into candesartan by cleavage of the cilexetil moiety in the gastrointestinal tract during absorption and achieves peak plasma concentrations at 4 h. 46 Candesartan cilexetil is not detected in plasma after oral administration. The other AT 1 receptor antagonists (irbesartan, valsartan, eprosartan, and telmisartan) are neither prodrugs nor active without bioconversion. After oral administration AT 1 receptor antagonists are rapidly absorbed (time for peak plasma levels: 0.5-4 h) but they have a wide range of bioavailability (from a low of 13% for eprosartan to a high of 60-80% for irbesartan); food does not influence the bioavail- ability, except for valsartan (reduction in 40-50%) and eprosartan. 46 AT 1 receptor antagonists are highly bound to plasma proteins, ranging from 90% with irbesartan to more than 99% with candesartan and EXP3174. Despite the high protein binding, these agents achieve pharmacologically significant concentrations at the receptor, as evident by their ability to antagonise angiotensin II mediated effects. 45, 47 The elimination characteristics of the AT 1 receptor antagonists differ in term of both half-life and route. Losartan has an elimination half-life of 2 h, suggesting that it is a short-acting agent, but its metabolite EXP3174 has an elimination of 6 to 9 h, comparable to those of valsartan and eprosartan. In comparison, candesartan cilexetil (9 h), irbesartan (11-15 h ) and telmisartan (24 h) are longer acting. 48, 49 The major route of elimination of the AT 1 receptor antagonists is unrelated to half-life. Losartan, valsartan, and irbesartan primarily undergo biliary excretion, with 70% to 80% of the dose eliminated in faeces, whereas eprosartan is almost exclusively eliminated by the kidneys. 50 In contrast, candesartan cilexetil undergoes both renal and biliary elimination, with approximately 60% excreted in the urine and 40% in the faeces.
Effect on left ventricular hypertrophy
ACE inhibitors are particularly effective in reducing and perhaps preventing left ventricular hypertrophy in hypertensive patients mediated by several mechanisms, such as the reduction of circulating angiotensin II and aldosterone and increment of bradykinin. 51, 52 Losartan and other AT 1 antagonists reduce left ventricular hypertrophy in spontaneously hypertensive rats; 53 even at dosages that do not effect either blood pressure or the circulating renin-angiotensin system. 54 Thü rmann PA et al 55 in a double-blind randomised trial on 69 previously untreated hypertensive patients comparing valsartan (80 to 160 mg daily) with atenolol (50 to 100 mg daily) over 8 months, found that valsartan reduced left ventricular mass index to a higher extent than atenolol with similar reduction in systolic and diastolic blood pressure. Further documentation of the effects on left ventricular hypertrophy and long-term benefit and risk reduction will have to be evaluated in other trials.
Side effects
The AT 1 receptor antagonists have low incidence of adverse effects even in the elderly. The adverse effects profile seems to be similar of placebo control. Goldberg et al 56 reported data on the safety and tolerability of losartan in 2900 hypertensive patients treated in double-blind clinical trials. Headache (14.1%), upper respiratory infection (6.5%), dizziness (14.1%), asthenia/fatigue (3.8%), and cough (3.1%) were the clinical side effects most often reported in patients treated with losartan; and the frequency reported during the placebo were 17.2%, 5.6%, 2.4%, 3.9% and 2.6% respectively. The incidence of cough is similar to diuretic or placebo in contrast with an ACE inhibitor with an average incidence of 8.8%. 57 Chan P et al 58 compared the incidence of cough with the ACE inhibitor lisinopril, and the diuretic metolazone, with losartan in elderly hypertensive patient with previous histories of ACE inhibitorinduced cough, in a randomised, double-blind, parallel group comparison of each drug during 10 weeks in 84 patients. The incidence of cough with losartan (18%) was significantly lower than lisinopril (97%), and similar to that for metolazone (21%).
Dizziness, upper respiratory tract infection, back pain, sinusitis, diarrhoea and pharyngitis have been reported to be 1 to 2% higher that placebo with different agents. 57 Eprosartan, in a trial including 243 patients with mild-to-moderate hypertension, controlled blood pressure in 42%, with a dosage of 600 mg daily the total number of adverse events was similar in the eprosartan and placebo groups. 48 AT 1 receptor antagonists do not modify glucose tolerance with either cholesterol or triglyceride levels.
Drugs that act directly on renin-angiotensin system can cause fetal and neonatal morbidity and death when administered to pregnant women, any of the AT 1 receptor antagonists should not be used during pregnancy and should be discontinued immediately as pregnancy is detected.
As a result of a favourable safety profile, discontinuation rate with AT 1 receptor antagonists is low. In a study, it was shown that AT 1 receptor antagonists had the highest 1-year compliance rate among five major classes of antihypertensive drugs.
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Conclusions
AT 1 receptor antagonists are a new class of drugs used to treated hypertensive patients. They are effective in reducing systolic and diastolic blood pressure in mild-to-moderate hypertension in about 40% of treated patients when they are used in monotherapy; but its efficacy increment to 60 to 70% when used in combination with low dose diuretic agent. Blood pressure is reduced with about equal efficacy compared with ACE-inhibitors, beta-blockers and calcium channel blockers when these drugs are used in monotherapy.
AT 1 receptor antagonists could be used in combination with most other antihypertensive agents in more severe hypertension.
AT 1 receptors antagonists represent an important option for the treatment of hypertension, especially in patients who have been using ACE inhibitors and who present with cough or angioedema. Tolerability has been reported to be excellent with the use of AT 1 receptor antagonists.
It remains to be determined whether the pharmadynamic and pharmacokinetic differences among angiotensin II receptor blockers provide a clinically significant impact on reduction of blood pressure or on long-term outcomes, such as the incidence of stroke and myocardial infarction.
The place in the antihypertensive therapy in a special population and different clinical conditions, such as left ventricular hypertrophy, associated heart failure, diabetes, and renal disease, has to be determined in a further large prospective clinical trial, however results so far, look like promising. 
